| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1136/BMJ.C4737 |
| P724 | Internet Archive ID | pubmed-PMC2954275 |
| P3181 | OpenCitations bibliographic resource ID | 1453915 |
| P932 | PMC publication ID | 2954275 |
| P698 | PubMed publication ID | 20940209 |
| P50 | author | Martin Gerken | Q59679771 |
| Monika Lelgemann | Q30380087 | ||
| P2093 | author name string | Mandy Kromp | |
| Martin Härter | |||
| Thomas Kaiser | |||
| Beate Wieseler | |||
| Ulrich Grouven | |||
| Michaela F Kerekes | |||
| Dirk Eyding | |||
| P2860 | cites work | Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder | Q48732957 |
| The selective noradrenaline re-uptake inhibitor reboxetine has an early onset of antidepressant action | Q48735977 | ||
| Do noradrenaline and serotonin differentially affect social motivation and behaviour? | Q48759711 | ||
| Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning | Q48770291 | ||
| A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder | Q50218537 | ||
| Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder | Q53863279 | ||
| Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder | Q77374064 | ||
| Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine | Q79746757 | ||
| Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 | ||
| Reporting bias in medical research - a narrative review | Q21203744 | ||
| Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy | Q23791313 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Outcome reporting in industry-sponsored trials of gabapentin for off-label use | Q28264491 | ||
| Dissemination and publication of research findings: an updated review of related biases | Q28274123 | ||
| Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles | Q29618882 | ||
| Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 | ||
| Systematic review of the empirical evidence of study publication bias and outcome reporting bias | Q29619094 | ||
| Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder | Q30310780 | ||
| Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry | Q30799658 | ||
| Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data | Q30925583 | ||
| The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. | Q33976127 | ||
| Publication and related biases | Q33994869 | ||
| Relationship between drug company funding and outcomes of clinical psychiatric research | Q33998328 | ||
| The promises and pitfalls of reboxetine | Q34280197 | ||
| Advanced methods in meta-analysis: multivariate approach and meta-regression. | Q34523076 | ||
| Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications | Q34534086 | ||
| Influence of drug company authorship and sponsorship on drug trial outcomes | Q34643867 | ||
| "Wish bias" in antidepressant drug trials? | Q35810532 | ||
| Reboxetine: a norepinephrine selective reuptake pump inhibitor | Q35873572 | ||
| Publication bias: evidence of delayed publication in a cohort study of clinical research projects | Q36246225 | ||
| Publication bias: the case for an international registry of clinical trials | Q39795619 | ||
| Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression | Q43914824 | ||
| Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression | Q44097675 | ||
| Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. | Q44107460 | ||
| Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients | Q44255099 | ||
| The antidepressant efficacy of reboxetine in patients with severe depression | Q44289041 | ||
| The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. | Q44996882 | ||
| Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine | Q46735457 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | oct12 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | major depressive disorder | Q42844 |
| heterocyclic compound | Q193430 | ||
| placebo | Q269829 | ||
| antidepressant | Q76560 | ||
| serotonin | Q167934 | ||
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| mechanism of action | Q3271540 | ||
| morpholine | Q73589551 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | c4737 | |
| P577 | publication date | 2010-10-12 | |
| P13046 | publication type of scholarly work | systematic review | Q1504425 |
| review article | Q7318358 | ||
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials | |
| P478 | volume | 341 |
| Q47672969 | 'One mission accomplished, more important ones remain': commentary on Every-Palmer, S., Howick, J. (2014) How evidence-based medicine is failing due to biased trials and selective publication. Journal of Evaluation in Clinical Practice, 20 (6), 908- |
| Q57412712 | A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports |
| Q34013434 | A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation |
| Q35981773 | A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population |
| Q34046947 | A model for dissemination and independent analysis of industry data |
| Q30374324 | A neurocognitive model for understanding treatment action in depression |
| Q38115737 | A review of the adverse effects and safety of noradrenergic antidepressants |
| Q30575381 | Access to regulatory data from the European Medicines Agency: the times they are a-changing |
| Q21144599 | Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes |
| Q43526983 | Adrenergic Receptor Gene Variation and Selective Norepinephrine Reuptake Inhibitors |
| Q33906501 | Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals |
| Q33971236 | Agomelatine - is it another reboxetine? Another case of publication bias |
| Q34038812 | Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial |
| Q92112947 | An Evaluation of Publication Bias in High-Impact Orthopaedic Literature |
| Q28236293 | Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies |
| Q34629841 | Antidepressant medications reduce subcortical–cortical resting-state functional connectivity in healthy volunteers |
| Q38080019 | Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline? |
| Q44889816 | Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: a possible role in antidepressant therapy? |
| Q43695621 | Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. |
| Q33583083 | Are these results trustworthy? A guide for reading the medical literature |
| Q56915696 | Bad medicine |
| Q53643814 | Benefit assessment of drugs |
| Q33710440 | Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications |
| Q34681386 | Blood pressure lowering efficacy of renin inhibitors for primary hypertension |
| Q82862511 | Bringing evidence to practice: obstacles and barriers |
| Q38205025 | Cardiovascular adverse effects of newer antidepressants |
| Q98952041 | Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients |
| Q24202141 | Citalopram versus other anti-depressive agents for depression |
| Q48642462 | Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians. |
| Q36650066 | Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports |
| Q38614034 | Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect |
| Q28534273 | Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data |
| Q38003344 | Comprehensive review of factors implicated in the heterogeneity of response in depression |
| Q47644422 | Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation |
| Q33885304 | Data transparency - an ethical imperative? Approaching the issues |
| Q42544317 | Declaration of transparency for each research article |
| Q38265929 | Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review |
| Q37835982 | Developing predictive CSF biomarkers—A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine |
| Q37940446 | Disclosure of clinical trial results when product development is abandoned. |
| Q47340338 | Discontinuation and non-publication of neurodegenerative disease trials: a cross-sectional analysis. |
| Q47592178 | Discussion of "quantifying publication bias in meta-analysis" by Liu et al. |
| Q47140896 | Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients |
| Q48765199 | Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial |
| Q27022217 | Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis |
| Q49825398 | Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis |
| Q34765596 | Efficacy of new generation antidepressants: differences seem illusory |
| Q28236453 | Emerging drugs for the treatment of tobacco dependence: 2014 update |
| Q88380844 | Empirical Comparison of Publication Bias Tests in Meta-Analysis |
| Q36610804 | Epidemiology and treatment of mood disorders in a day hospital setting from 1996 to 2007: an Italian study |
| Q38476909 | Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. |
| Q86499031 | Evolution of evidence-based medicine to detect evidence mutations |
| Q24288672 | Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries |
| Q24202410 | Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis |
| Q35943880 | How do authors of systematic reviews deal with research malpractice and misconduct in original studies? A cross-sectional analysis of systematic reviews and survey of their authors |
| Q30776047 | How health technology assessment agencies address the issue of unpublished data |
| Q28482475 | Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials |
| Q35151458 | Impact of inclusion of industry trial results registries as an information source for systematic reviews |
| Q38137886 | Improving study design for antidepressant effectiveness assessment. |
| Q26995526 | Inadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic review |
| Q58538262 | Incorporating Gender and Sex Dimensions in Medical Research |
| Q28611347 | Increasing value and reducing waste: addressing inaccessible research |
| Q48216988 | Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review |
| Q47158437 | Interventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trials |
| Q55340265 | Is publication bias present in gastroenterological research? An analysis of abstracts presented at an annual congress. |
| Q90327121 | Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have |
| Q39540813 | Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER. |
| Q47098457 | Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants' Efficacy and Harm |
| Q50621196 | Mood and personality effects in healthy participants after chronic administration of sertraline |
| Q95598079 | Network meta-analysis of antidepressants |
| Q24197463 | Neuraminidase inhibitors for preventing and treating influenza in adults and children |
| Q24203905 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children |
| Q24235164 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children - a review of clinical study reports |
| Q39323947 | New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease |
| Q38091914 | Noradrenergic modulation of cognition: Therapeutic implications |
| Q35844255 | Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study |
| Q47099566 | Outcomes in randomised controlled trials in prevention and management of carious lesions: a systematic review. |
| Q38120495 | Pharmacological Management of Depression in Patients with Cancer: Practical Considerations |
| Q38006412 | Pharmacological Treatment of Unipolar Depression |
| Q38099042 | Pharmacological management of unipolar depression |
| Q33803327 | Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. |
| Q90595190 | Preprints: What is their role in medical journals? |
| Q40542349 | Protocol registration and selective outcome reporting in recent psychiatry trials: new antidepressants and cognitive behavioural therapies |
| Q53086474 | Publication Bias in Epidemiological Studies |
| Q38108574 | Publication Bias, with a Focus on Psychiatry: Causes and Solutions |
| Q24282598 | Publication bias: what are the challenges and can they be overcome? |
| Q37857762 | Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register |
| Q28541228 | Quality and quantity of information in summary basis of decision documents issued by health Canada |
| Q37949399 | Quality, bias and service user experience in healthcare: 10 years of mental health guidelines at the UK National Collaborating Centre for Mental Health |
| Q57800224 | Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study |
| Q28554247 | Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review |
| Q38814635 | Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials |
| Q34264254 | Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports |
| Q38606623 | Role of the 5-HTTLPR and SNP Promoter Polymorphisms on Serotonin Transporter Gene Expression: a Closer Look at Genetic Architecture and In Vitro Functional Studies of Common and Uncommon Allelic Variants |
| Q42376820 | Search for unpublished data by systematic reviewers: an audit |
| Q24197825 | Selective noradrenaline reuptake inhibitors for schizophrenia |
| Q47552058 | Selective noradrenaline reuptake inhibitors for schizophrenia. |
| Q92966521 | Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus et al |
| Q89512724 | Stakeholder views on publication bias in health services research |
| Q27316649 | Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations |
| Q48012409 | Stereodivergent synthesis of all the four stereoisomers of antidepressant reboxetine |
| Q89646548 | Sticking to principles and anticipating outcomes |
| Q33602408 | Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research |
| Q97553480 | The Hong Kong Principles for assessing researchers: Fostering research integrity |
| Q38861612 | The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review |
| Q38014591 | The effect of neutering on the risk of mammary tumours in dogs--a systematic review |
| Q43676192 | The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress |
| Q93235740 | The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports |
| Q21563018 | The imperative to share clinical study reports: recommendations from the Tamiflu experience |
| Q35090223 | The importance of norepinephrine in depression |
| Q35137131 | The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse |
| Q25118387 | The need and drive for open data in biomedical publishing |
| Q51465921 | The role of the funnel plot in detecting publication and related biases in meta-analysis |
| Q92559652 | The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses |
| Q57170319 | The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors |
| Q30605821 | Tools for assessing the content of guidelines are needed to enable their effective use--a systematic comparison |
| Q39740359 | Toward evidence-based medical statistics: a Bayesian analysis of double-blind placebo-controlled antidepressant trials in the treatment of anxiety disorders. |
| Q42015236 | Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. |
| Q51383209 | Trends in the dispensation of antidepressant drugs over the past decade (2000-2010) in Andalusia, Spain |
| Q89924349 | What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on Jørgensen et al |
| Q48939446 | Where is the room for improvement in the drug treatment of depression and anxiety? |
| Q24288940 | Which placebo to cure depression? A thought-provoking network meta-analysis |
| Q28732492 | Why we need easy access to all data from all clinical trials and how to accomplish it |
| Q38123516 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders |
| Q86705250 | [Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part II: General Aspec |
Search more.